文献速递前列腺癌

临床局限前列腺癌原发治疗后的生活质量结局:系统综述

Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
PubMed 文献 · Eur Urol · 2017-07-27

该系统综述纳入18项比较研究(3项随机对照试验和15项非随机比较研究),共13604例临床局限前列腺癌患者,评估主动监测、手术、外照射放疗和近距离放疗对疾病特异性生活质量的影响。随访至6年时,主动监测对癌症特异性生活质量影响最小,手术对排尿和性功能有负面影响,外照射放疗对肠道功能有负面影响。

要点

  • 随访至6年,主动监测对癌症特异性生活质量影响最小。
  • 与主动监测和外照射放疗相比,手术对排尿和性功能有负面影响。
  • 与主动监测和手术相比,外照射放疗对肠道功能有负面影响。

核心结论

  • 这是首个仅使用经验证的癌症特异性患者报告结局指标、比较不同原发治疗对临床局限前列腺癌男性癌症特异性生活质量影响的系统综述。
  • 有可靠证据表明,临床局限前列腺癌原发治疗的选择对患者生活质量有不同影响,应在治疗前咨询中与患者详细讨论。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、AMED、PsycINFO和Cochrane Library,纳入18项研究,包括3项随机对照试验(随访范围60-72个月)和15项非随机比较研究(随访范围12-180个月),共招募13604例患者。
  • 两项随机对照试验招募的队列较小,仅一项被判定为低偏倚风险;观察性研究的证据质量低至中等。

主要发现

  • 在最长6年的随访中,主动监测对癌症特异性生活质量的影响最小。
  • 与主动监测和外照射放疗相比,手术对排尿功能和性功能有负面影响。
  • 与主动监测和手术相比,外照射放疗对肠道功能有负面影响。
  • 一项小型随机对照试验的数据报告,近距离放疗在治疗后1年对排尿功能有负面影响,但5年时未报告显著的泌尿系统毒性。

临床怎么用

  • 有可靠证据表明,临床局限前列腺癌原发治疗的选择对患者生活质量有不同影响,应在治疗前咨询中与患者详细讨论。
  • 作者指出,主动监测对癌症特异性生活质量影响最小,手术主要与排尿和性问题相关,外照射放疗主要与肠道问题相关。
  • 作者指出,适合近距离放疗的男性在治疗后一年内报告排尿问题,但随后生活质量逐渐恢复到治疗前水平。

局限性

  • 两项随机对照试验招募的队列较小,仅一项被判定为低偏倚风险。
  • 观察性研究的证据质量低至中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Current evidence-based management for clinically localised prostate cancer includes active surveillance, surgery, external beam radiotherapy (EBRT) and brachytherapy. The impact of these treatment modalities on quality of life (QoL) is uncertain. OBJECTIVE: To systematically review comparative studies investigating disease-specific QoL outcomes as assessed by validated cancer-specific patient-reported outcome measures with at least 1 yr of follow-up after primary treatment for clinically localised prostate cancer. EVIDENCE ACQUISITION: MEDLINE, EMBASE, AMED, PsycINFO, and Cochrane Library were searched to identify relevant studies. Studies were critically appraised for the risk of bias. A narrative synthesis was undertaken. EVIDENCE SYNTHESIS: Of 11486 articles identified, 18 studies were eligible for inclusion, including three randomised controlled trials (RCTs; follow-up range: 60-72 mo) and 15 nonrandomised comparative studies (follow-up range: 12-180 mo) recruiting a total of 13604 patients. Two RCTs recruited small cohorts and only one was judged to have a low risk of bias. The quality of evidence from observational studies was low to moderate. For a follow-up of up to 6 yr, active surveillance was found to have the lowest impact on cancer-specific QoL, surgery had a negative impact on urinary and sexual function when compared with active surveillance and EBRT, and EBRT had a negative impact on bowel function when compared with active surveillance and surgery. Data from one small RCT reported that brachytherapy has a negative impact on urinary function 1 yr post-treatment, but no significant urinary toxicity was reported at 5 yr. CONCLUSIONS: This is the first systematic review comparing the impact of different primary treatments on cancer-specific QoL for men with clinically localised prostate cancer, using validated cancer-specific patient-reported outcome measures only. There is robust evidence that choice of primary treatment for localised prostate cancer has distinct impacts on patients' QoL. This should be discussed in detail with patients during pretreatment counselling. PATIENT SUMMARY: Our review of the current evidence suggests that for a period of up to 6 yr after treatment, men with localised prostate cancer who were managed with active surveillance reported high levels of quality of life (QoL). Men treated with surgery reported mainly urinary and sexual problems, while those treated with external beam radiotherapy reported mainly bowel problems. Men eligible for brachytherapy reported urinary problems up to a year after therapy, but then their QoL returned gradually to as it was before treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lardas M, Liew M, van den Bergh RC, et al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017. PMID: 28757301. doi:10.1016/j.eururo.2017.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。